Featured
Combined Risk Factors Linked to Late Parkinson Disease
Trial Briefs Sep 2, 2026
Drug Approvals Sep 1, 2026
Clinic Moves Aug 31, 2026
Discover the latest stroke rehabilitation guidelines from American Heart Association for improved recovery outcomes with...
Botox migraine therapy is gaining attention as it shows relief for migraine and spasticity, providing...
FDA approves new treatments for brain disorders, including Tourette syndrome, with priority review for ecopipam...
Read our latest Drug Approvals articles.
GammaTile slows brain tumor regrowth in glioblastoma patients with promising results from the GESTALT trial...
FDA Week: New blood test for Alzheimer's disease approved. See how Elecsys pTau217 helps identify...
Factor XIa inhibitors are emerging as a promising antithrombotic option to reduce recurrent strokes, offering...
Study reveals combined risk factors significantly increase late-onset Parkinson disease risk, with multiple exposures showing synergistic effects beyond individ
Study reveals combined risk factors significantly increase late-onset Parkinson disease risk, with multiple exposures showing synergistic effects beyond individ
GammaTile slows brain tumor regrowth in glioblastoma patients with promising results from the GESTALT trial period.
Discover the latest stroke rehabilitation guidelines from American Heart Association for improved recovery outcomes with updated recommendations.
FDA approves Oveporexton (Orzeyful) for Type 1 Narcolepsy, first therapy to restore orexin signaling. Learn how it tackles the root...
FDA Week: New blood test for Alzheimer's disease approved. See how Elecsys pTau217 helps identify amyloid pathology in adults 55...
Botox migraine therapy is gaining attention as it shows relief for migraine and spasticity, providing a targeted alternative to systemic...
FDA approval of Avulux migraine lenses offers an over‑the‑counter solution to reduce photophobia for migraine sufferers aged 12+, complementing existing...
Gene therapy MPS II stalls as the FDA places a clinical hold on RGX-121 after MRI scans revealed spinal abnormalities,...
Factor XIa inhibitors are emerging as a promising antithrombotic option to reduce recurrent strokes, offering better protection than aspirin or...
FDA approves new treatments for brain disorders, including Tourette syndrome, with priority review for ecopipam drug application.